Free Trial
NASDAQ:CRBU

Caribou Biosciences Q3 2024 Earnings Report

Caribou Biosciences logo
$1.88 +0.03 (+1.35%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Caribou Biosciences EPS Results

Actual EPS
-$0.38
Consensus EPS
-$0.44
Beat/Miss
Beat by +$0.06
One Year Ago EPS
N/A

Caribou Biosciences Revenue Results

Actual Revenue
$2.02 million
Expected Revenue
$3.37 million
Beat/Miss
Missed by -$1.35 million
YoY Revenue Growth
N/A

Caribou Biosciences Announcement Details

Quarter
Q3 2024
Time
After Market Closes
Conference Call Date
Wednesday, November 6, 2024
Conference Call Time
12:30PM ET

Upcoming Earnings

Caribou Biosciences' Q3 2025 earnings is scheduled for Wednesday, November 5, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Caribou Biosciences Earnings Headlines

Caribou Biosciences (NASDAQ:CRBU) Upgraded at Wall Street Zen
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
What is Leerink Partnrs' Estimate for CRBU FY2025 Earnings?
CRBU Q3 EPS Forecast Boosted by Brookline Capital Management
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU), a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

View Caribou Biosciences Profile

More Earnings Resources from MarketBeat